世界の心血管疾患市場は2023年に約1億7,155万米ドルと評価され、2024年から2032年の予測期間中に5％という堅調な成長率で拡大すると予想されています。心臓や血管に影響を及ぼす心血管疾患は、世界的な死亡原因のひとつとなっています。このカテゴリーの疾患は主に高齢者が罹患しており、心血管治療薬の一貫した使用が必要です。心血管疾患の重症度により、突然の中止は患者の健康に重大なリスクをもたらす可能性があるため、薬剤の長期使用が必要になることがよくあります。
市場は、座りがちなライフスタイルや高齢化による心血管疾患の発生率の驚くべき増加など、いくつかの重要な要因によって動かされています。 WHOによると、非活動的なライフスタイルが人口の60%〜85%に蔓延しており、これが心血管治療薬の需要の増加に寄与しています。さらに、Selexipag錠剤やNorliqva経口液剤の承認など、FDAからの規制当局の承認は、心血管治療のパイプラインの成長を浮き彫りにしています。これらの開発は、さまざまな心血管疾患に対処する上で重要であり、それによって市場の成長を推進します。
これに加えて、特に高齢化人口の間で高血圧症の有病率が上昇しているため、チャンスは豊富にあります。高齢者人口が世界的に拡大するにつれ、高血圧治療の需要も増加し、市場の成長をさらに加速させています。また、小売薬局は、そのアクセスのしやすさと利便性により、心血管疾患の患者を惹きつけており、医薬品の流通においてますます重要な役割を果たしています。
しかし、特に複雑な心血管治療を実施できる熟練した医療専門家の不足など、課題は依然として残っています。さらに、吐き気、胃のむかつき、勃起不全などの心血管治療薬に関連する副作用が市場の拡大を妨げる可能性があります。それにもかかわらず、革新的な治療アプローチへの注目の高まりと研究開発への投資の増加により、業界は引き続き前進しています。
世界の心血管疾患市場調査の対象となる主要地域には、アジア太平洋地域、北アメリカ、ヨーロッパ、ラテンアメリカ、世界のその他の地域が含まれます。北アメリカは、収益の面で世界の心血管疾患市場で支配的な地域です。この地域の市場の成長は、最先端の研究開発イニシアチブ、高度な医療インフラ、心臓病の高い有病率などの要因によるものと考えられています。一方、アジア太平洋地域の市場は、急成長する医療施設、多数のジェネリック医薬品メーカー、政府の支援的な取り組みによって、予測期間中に最も速い速度で成長すると予想されています。
目次
Table of Contents
Chapter 1. Global Cardiovascular Disease Market Executive Summary
1.1. Global Cardiovascular Disease Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Diseases
1.3.2. By Treatment
1.3.3. By Route of Administration
1.3.4. By End-User
1.3.5. By Distribution Channel
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Cardiovascular Disease Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.4. Demand Side Analysis
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global Cardiovascular Disease Market Dynamics
3.1. Market Drivers
3.1.1. Increase in Cardiovascular Diseases
3.1.2. Rising FDA Approvals
3.2. Market Challenges
3.2.1. Lack of Skilled Professionals
3.2.2. Side Effects of Cardioselective Beta Blockers
3.3. Market Opportunities
3.3.1. Rising Prevalence of Hypertension
3.3.2. Increasing Demand for Retail Pharmacies
Chapter 4. Global Cardiovascular Disease Market Industry Analysis
4.1. Porter’s Five Forces Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunity
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Analyst Recommendation & Conclusion
Chapter 5. Global Cardiovascular Disease Market Size & Forecasts by Diseases (2022-2032)
5.1. Segment Dashboard
5.2. Global Cardiovascular Disease Market: Disease Revenue Trend Analysis, 2022 & 2032 (USD Million)
5.2.1. Hypertension
5.2.2. Dyslipidemia
5.2.3. Inflammatory Heart Disease
5.2.4. Ischemic Heart Disease
5.2.5. Others
Chapter 6. Global Cardiovascular Disease Market Size & Forecasts by Treatment (2022-2032)
6.1. Segment Dashboard
6.2. Global Cardiovascular Disease Market: Treatment Revenue Trend Analysis, 2022 & 2032 (USD Million)
6.2.1. Antiplatelet Agents
6.2.2. Beta-Blockers
6.2.3. Angiotensin-Converting Enzyme Inhibitors
6.2.4. Others
Chapter 7. Global Cardiovascular Disease Market Size & Forecasts by Route of Administration (2022-2032)
7.1. Segment Dashboard
7.2. Global Cardiovascular Disease Market: Route of Administration Revenue Trend Analysis, 2022 & 2032 (USD Million)
7.2.1. Oral
7.2.2. Parenteral
7.2.3. Others
Chapter 8. Global Cardiovascular Disease Market Size & Forecasts by End-User (2022-2032)
8.1. Segment Dashboard
8.2. Global Cardiovascular Disease Market: End-User Revenue Trend Analysis, 2022 & 2032 (USD Million)
8.2.1. Hospitals
8.2.2. Homecare
8.2.3. Specialty Clinics
8.2.4. Others
Chapter 9. Global Cardiovascular Disease Market Size & Forecasts by Distribution Channel (2022-2032)
9.1. Segment Dashboard
9.2. Global Cardiovascular Disease Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Million)
9.2.1. Hospital Pharmacy
9.2.2. Online Pharmacy
9.2.3. Retail Pharmacy
Chapter 10. Global Cardiovascular Disease Market Size & Forecasts by Region (2022-2032)
10.1. North America Cardiovascular Disease Market
10.1.1. U.S. Cardiovascular Disease Market
10.1.1.1. Diseases breakdown size & forecasts, 2022-2032
10.1.1.2. Treatment breakdown size & forecasts, 2022-2032
10.1.1.3. Route of Administration breakdown size & forecasts, 2022-2032
10.1.1.4. End User breakdown size & forecasts, 2022-2032
10.1.1.5. Distribution Channel breakdown size & forecasts, 2022-2032
10.1.2. Canada Cardiovascular Disease Market
10.1.3. Mexico Cardiovascular Disease Market
10.2. Europe Cardiovascular Disease Market
10.2.1. U.K. Cardiovascular Disease Market
10.2.2. Germany Cardiovascular Disease Market
10.2.3. France Cardiovascular Disease Market
10.2.4. Italy Cardiovascular Disease Market
10.2.5. Spain Cardiovascular Disease Market
10.2.6. Rest of Europe Cardiovascular Disease Market
10.3. Asia Pacific Cardiovascular Disease Market
10.3.1. China Cardiovascular Disease Market
10.3.2. Japan Cardiovascular Disease Market
10.3.3. India Cardiovascular Disease Market
10.3.4. Australia Cardiovascular Disease Market
10.3.5. South Korea Cardiovascular Disease Market
10.3.6. Rest of Asia Pacific Cardiovascular Disease Market
10.4. Latin America Cardiovascular Disease Market
10.4.1. Brazil Cardiovascular Disease Market
10.4.2. Argentina Cardiovascular Disease Market
10.4.3. Rest of Latin America Cardiovascular Disease Market
10.5. Middle East & Africa Cardiovascular Disease Market
10.5.1. Saudi Arabia Cardiovascular Disease Market
10.5.2. South Africa Cardiovascular Disease Market
10.5.3. Rest of Middle East & Africa Cardiovascular Disease Market
Chapter 11. Competitive Intelligence
11.1. Key Company SWOT Analysis
11.1.1. Company 1
11.1.2. Company 2
11.1.3. Company 3
11.2. Top Market Strategies
11.3. Company Profiles
11.3.1. F. Hoffmann-La Roche Ltd
11.3.1.1. Key Information
11.3.1.2. Overview
11.3.1.3. Financial (Subject to Data Availability)
11.3.1.4. Product Summary
11.3.1.5. Market Strategies
11.3.2. Bayer AG
11.3.3. Novartis AG
11.3.4. Pfizer Inc.
11.3.5. GSK Plc
11.3.6. Sun Pharmaceutical Industries Ltd
11.3.7. Mylan N.V.
11.3.8. Teva Pharmaceutical Industries Ltd
11.3.9. Zydus Group
11.3.10. Glenmark Pharmaceuticals Inc.
11.3.11. Fresenius Kabi AG
11.3.12. Lupin
11.3.13. Capricor Therapeutics
11.3.14. Zensun
11.3.15. Janssen Pharmaceuticals, Inc.
Chapter 12. Research Process
12.1. Research Process
12.1.1. Data Mining
12.1.2. Analysis
12.1.3. Market Estimation
12.1.4. Validation
12.1.5. Publishing
12.2. Research Attributes
List of Tables
TABLE 1. Global Cardiovascular Disease Market Scope
TABLE 2. Global Cardiovascular Disease Market Estimates & Forecasts by Region (2022-2032) (USD Million)
TABLE 3. Global Cardiovascular Disease Market Estimates & Forecasts by Diseases (2022-2032) (USD Million)
TABLE 4. Global Cardiovascular Disease Market Estimates & Forecasts by Treatment (2022-2032) (USD Million)
TABLE 5. Global Cardiovascular Disease Market Estimates & Forecasts by Route of Administration (2022-2032) (USD Million)
TABLE 6. Global Cardiovascular Disease Market Estimates & Forecasts by End-User (2022-2032) (USD Million)
TABLE 7. Global Cardiovascular Disease Market Estimates & Forecasts by Distribution Channel (2022-2032) (USD Million)
TABLE 8. North America Cardiovascular Disease Market Estimates & Forecasts (2022-2032) (USD Million)
TABLE 9. Europe Cardiovascular Disease Market Estimates & Forecasts (2022-2032) (USD Million)
TABLE 10. Asia Pacific Cardiovascular Disease Market Estimates & Forecasts (2022-2032) (USD Million)
...
(This list is not complete; the final report contains more than 100 tables. The list may be updated in the final deliverable.)
List of Figures
FIG 1. Global Cardiovascular Disease Market, Research Methodology
FIG 2. Global Cardiovascular Disease Market, Market Estimation Techniques
FIG 3. Global Market Size Estimates & Forecast Methods
FIG 4. Global Cardiovascular Disease Market, Key Trends 2023
FIG 5. Global Cardiovascular Disease Market, Growth Prospects (2022-2032)
FIG 6. Global Cardiovascular Disease Market, Porter's Five Forces Model
FIG 7. Global Cardiovascular Disease Market, PESTEL Analysis
FIG 8. Global Cardiovascular Disease Market, Value Chain Analysis
FIG 9. Global Cardiovascular Disease Market by Segment (2022 & 2032) (USD Million)
FIG 10. North America Cardiovascular Disease Market Size & Forecasts (2022-2032)
FIG 11. Europe Cardiovascular Disease Market Size & Forecasts (2022-2032)
FIG 12. Asia Pacific Cardiovascular Disease Market Size & Forecasts (2022-2032)
...
(This list is not complete; the final report contains more than 50 figures. The list may be updated in the final deliverable.)
